This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, G.
Right arrow Articles by Appelbaum, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, G.
Right arrow Articles by Appelbaum, P. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2005, p. 770-772, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.770-772.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide

Gengrong Lin, Kim Credito, Lois M. Ednie, and Peter C. Appelbaum*

Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania

Received 11 June 2004/ Returned for modification 23 September 2004/ Accepted 11 October 2004


arrow
ABSTRACT
 
Dalbavancin, tested against 146 staphylococci, was more potent than other drugs tested, with an MIC at which 50% of staphylococci were inhibited of 0.03 µg/ml and an MIC at which 90% of staphylococci were inhibited of 0.06 µg/ml by microdilution. For all strains, MICs of vancomycin, linezolid, ranbezolid, oritavancin, daptomycin, and quinupristin-dalfopristin were ≤4.0 µg/ml. Dalbavancin was bactericidal at four times the MIC against all six strains tested.


arrow
TEXT
 
Emergence of staphylococci that are intermediate and resistant to methicillin and quinolone and recently to vancomycin, as well as the propensity of these organisms to cause serious systemic infections in immunocompromised hosts, necessitates other therapeutic modalities (2, 3, 10, 11, 15, 18, 21, 25). During 2002, two clinical strains of vancomycin-resistant Staphylococcus aureus (VRSA) carrying van(A), one from Detroit, Mich., and one from our hospital, were isolated (3). Most methicillin-resistant staphylococci are also resistant to available quinolones, such as ciprofloxacin, levofloxacin, gatifloxacin, and moxifloxacin (2, 10, 15, 18, 21). Thus, these last compounds may not be safely used in empirical therapy for patients with methicillin-resistant staphylococcal infections.

Dalbavancin is an experimental glycopeptide with a long half-life (4) with excellent activity against gram-positive aerobic and anaerobic bacteria (1, 4, 8, 13, 24). This study examined the susceptibilities of 146 staphylococci to dalbavancin compared to susceptibilities to vancomycin, teicoplanin, linezolid, ranbezolid, oritavancin, daptomycin, and quinupristin-dalfopristin by MIC and time-kill analysis. Although dalbavancin activity by MIC is well known, little has thus far been published on its kill kinetics against staphylococci.

Twenty-nine methicillin-resistant and 43 methicillin-susceptible S. aureus strains as well as 36 methicillin-resistant and 38 methicillin-susceptible coagulase-negative staphylococci were studied by microdilution, and six strains (three S. aureus strains and three coagulase-negative staphylococci: two methicillin resistant strains and one methicillin-susceptible strain in each group) were subjected to time-kill analysis. Sources of drugs were as follows: dalbavancin, Vicuron Pharmaceuticals, King of Prussia, Pa.; vancomycin, Sigma, Inc., St. Louis, Mo.; oritavancin (as LY 333328), Eli Lilly & Co., Indianapolis, Ind.; teicoplanin and quinupristin-dalfopristin, Aventis Pharma, Romainville, France; linezolid, Pfizer, Inc., Groton, Conn.; ranbezolid, Ranbaxy Laboratories, New Delhi, India; and daptomycin, Cubist Pharmaceuticals, Lexington, Mass. Microdilutions were performed as recommended by NCCLS (17) using commercially prepared trays (TREK, Inc., Westlake, Ohio) with dehydrated dalbavancin and all other drugs in the frozen state. MICs of vancomycin were read after a full 24-h incubation. Calcium was added to daptomycin wells, as recommended by NCCLS (17).

For time kills, tubes containing 5 ml of cation-adjusted Mueller-Hinton broth (BBL) with doubling antibiotic concentrations were inoculated with 5 x 105 to 5 x 106 CFU/ml and incubated at 35°C in a shaking water bath. Methods were modified from those described previously by our group, with added calcium used for daptomycin (17, 20).

Time-kill assays were analyzed by determining the numbers of strains which yielded a {Delta}log10 CFU/ml of –1, –2, and –3 at 0, 3, 6, 12, and 24 h compared to counts at time zero. Antimicrobials were considered bactericidal at the lowest concentration that reduced the original inoculum by ≥3 log10 CFU/ml (99.9%) at each of the time periods and bacteriostatic if the inoculum was reduced by 0 to <3 log10 CFU/ml. The lower limit was set at 30 colonies (300 CFU/ml). The problem of antibiotic carryover was addressed by dilution as described previously (19). We believe that spreading 0.1 ml of undiluted broth onto a plate containing 25 ml of medium would dilute the drug 1:250; further 10-fold dilutions would dilute drugs 1:2,500, 1:25,000, etc. With the concentrations of drugs used, only undiluted inocula would have had any potential for drug carryover and only plates with low counts (<1,000 CFU/ml) would likely be affected (19). The time course of bactericidal activity, as shown below, also confirmed lack of carry-over effects.

MICs for staphylococci are listed in Table 1. As can be seen, all compounds except teicoplanin (which was less active against coagulase-negative staphylococci, especially methicillin-resistant strains) were active against all strains irrespective of their methicillin susceptibilities. Dalbavancin was the most potent agent, with an MIC at which 50% of staphylococci were inhibited of 0.03 µg/ml and an MIC at which 90% of staphylococci were inhibited of 0.06 µg/ml. MICs of ranbezolid were lower than those of linezolid, especially against coagulase-negative strains. MICs of vancomycin were slightly higher (but still in the susceptible range) for coagulase-negative strains than for S. aureus. MICs of daptomycin and quinupristin-dalfopristin were similar, and MICs of oritavancin were similar to those of linezolid.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Microdilution MICs of dalbavancin compared to those of other agents

MICs for the six strains tested by time-kill are listed in Table 2, and kill kinetics are listed in Table 3. In these experiments, the MICs of dalbavancin determined by macrodilution were on average three times higher than microdilution MICs. As can be seen, dalbavancin, oritavancin, and daptomycin were bactericidal against all strains at four times the MIC after 24 h. Daptomycin and oritavancin both showed killing at early time periods. Vancomycin and teicoplanin were both bactericidal against four strains at four times the MIC after 24 h, while both oxazolidinones and quinupristin-dalfopristin were mainly bacteriostatic. In the case of dalbavancin, a lack of carry-over effects is demonstrated by relatively little killing at earlier time periods (3 to 12 h). In fact, one to four times the MIC of dalbavancin produced <1 log10 kill for all strains at 3 h of exposure, and ≥3 log10 kill of all six strains was attained only with 24 h of exposure to four times the MIC.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Macrodilution MICs for six staphylococcal strains used in time-kill experiments


View this table:
[in this window]
[in a new window]
  		TABLE 3. Time-kill results

Dalbavancin (formerly BI 397) is a semisynthetic derivative of the teioplanin-like glycopeptide A40926 which is more active in vitro against staphylococci than teicoplanin and vancomycin. Against streptococci (including penicillin-resistant strains), dalbavancin had activity comparable to that of teicoplanin but better than that of vancomycin (1, 4, 13, 24). In a study of more than 6,000 clinical isolates, Streit and colleagues showed excellent activity of dalbavancin against all gram-positive strains tested except for vanA enterococci (24), with an MIC range against S. aureus between ≤0.015 and 0.5 µg/ml. Jones and colleagues (13) did not demonstrate bactericidal activity with dalbavancin against two S. aureus strains after 24 h, but exact methodology was not provided. Candiani and colleagues showed bactericidal activity at 32 times the MIC after 24 h with one of two S. aureus strains tested (4); however, this MIC multiple was based on microtiter determination, rather than with tubes which we used for kill curves. In the present study, dalbavancin kill kinetics was similar to those of vancomycin and teicoplanin, i.e., slow bactericidal activity, and only at concentrations higher than the MIC, after 24 h. In an earlier study (3), we found dalbavancin to be bactericidal after 24 h at two times the MIC against the Hershey VRSA.

Against a collection of anaerobic gram-positive species and corynebacteria and using agar dilution MICs, dalbavancin had low MICs (≤2.0 µg/ml) against all species tested except for Clostridium clostridioforme and lactobacilli (8). MICs of dalbavancin on agar have been higher than those obtained in broth, for reasons that are under investigation. Additionally, differences between broth macrodilution and microdilution have been observed by others, and the basis for this is also under investigation, although maintaining the compound in solution and preventing adherence to tube, pipette, and flask walls by using a small amount of a wetting agent appear to improve interlaboratory reproducibility (B. Goldstein, personal communication). Dry-format trays (such as those used in the present study for microdilution MICs) do not require addition of wetting agent (B. Goldstein, personal communication). However, both macrodilution and microdilution MICs determined in our study are within the range of ≤0.015 to 0.5 µg/ml described by Streit et al. in a large survey (24). It appears reasonable to relate the kill kinetics pattern of dalbavancin (which was similar to those of vancomycin and teicoplanin) to the macrobroth MICs determined with the same tubes.

Due to its long half-life (ca. 8 days), dalbavancin is under investigation at a dosage interval of 1 week (4). A recently published study has shown that a regimen of two doses of dalbavancin administered 1 week apart is effective in treatment of complicated gram-positive bacterial skin and soft-tissue infections (22). Lefort and colleagues have recently reported that a single dose of dalbavancin was active against S. aureus with or without reduced glycopeptide susceptibility in an adult rabbit endocarditis model (14).

In the present study, dalbavancin was very active against all strains. MICs ranged from ≤ 0.015 to 0.25 µg/ml except with VRSA, for which the dalbavancin MIC was 0.5 µg/ml. Antistaphylococcal activities of other agents tested were as reported previously, with uniformly low MICs except for that of teicoplanin against coagulase-negative staphylococci (5-7, 9, 12, 16, 20, 23).

Results of these studies indicate a potential place for dalbavancin in therapy for staphylococcal infections, including those caused by methicillin- and vancomycin-resistant strains. Phase 3 clinical trials for the therapy of skin and skin structure infections have been completed, and analysis of the data is in progress.


arrow
ACKNOWLEDGMENTS
 
This study was supported by a grant from Vicuron Pharmaceuticals, King of Prussia, Pa.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail: pappelbaum{at}psu.edu. Back


arrow
REFERENCES
 
    1
  1. Anderegg, T. R., D. J. Biedenbach, and R. N. Jones. 2003. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity. Antimicrob. Agents Chemother. 41:2795-2796.
    2. 2
  2. Blumberg, H. M., D. Rimland, D. J. Carroll, P. Terry, and I. K. Wachsmuth. 1991. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J. Infect. Dis. 163:1279-1285.[Medline]
    3. 3
  3. Bozdogan, B., D. Esel, C. Whitener, F. A. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus isolated at Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868.[Abstract/Free Full Text]
    4. 4
  4. Candiani, G., M. Abbondi, M. Borgonovi, G. Romanò, and F. Parenti. 1999. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44:179-192.[Abstract/Free Full Text]
    5. 5
  5. Cercenado, E., F. Garcia-Garrote, and E. Bouza. 2001. In-vitro activity of linezolid against multiply resistant gram-positive clinical isolates. J. Antimicrob. Chemother. 47:77-81.[Abstract/Free Full Text]
    6. 6
  6. Cuny, C., and W. Witte. 2000. In vitro activity of linezolid against staphylococci. Clin. Microbiol. Infect. 6:328-333.[CrossRef][Medline]
    7. 7
  7. Diekema, D. J., and R. N. Jones. 2000. Oxazolidinones. A review. Drugs 59:7-16.
    8. 8
  8. Goldstein, E. J. C., D. M. Citron, C. V. Merrian, Y. Warren, K. Tyrrell, and H. T. Fernandez. 2003. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob. Agents Chemother. 47:1968-1971.[Abstract/Free Full Text]
    9. 9
  9. Henwood, C. J., D. M. Livermore, A. P. Johnson, D. James, M. Warner, A. Gardiner, and the Linezolid Study Group. 2000. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J. Antimicrob. Chemother. 46:931-940.[Abstract/Free Full Text]
    10. 10
  10. Hershow, R. C., W. F. Khayr, and P. C. Schreckenberger. 1998. Ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: associated factors and resistance to other antibiotics. Antimicrob. Agents Chemother. 5:213-220.
    11. 11
  11. Hiramatsu, K. 1998. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med. 104:7S—10S.
    12. 12
  12. Hoellman, D., G. Lin, L. M. Ednie, A. Rattan, M. R. Jacobs, and P. C. Appelbaum. 2003. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob. Agents Chemother. 47:1148-1150.[Abstract/Free Full Text]
    13. 13
  13. Jones, R. N., D. J. Biedenbach, D. M. Johnson, and M. A. Pfaller. 2001. In vitro evaluation of BI 937, a novel glycopeptide antimicrobial agent. J. Chemother. 13:244-254.[Medline]
    14. 14
  14. Lefort, A., J. Pavie, L. Garry, F. Chau, and B. Fantin. 2004. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob. Agents Chemother. 48:1061-1064.[Abstract/Free Full Text]
    15. 15
  15. Linde, H. J., M. Schmidt, E. Fuchs, U. Reischl, H. H. Niller, and N. Lehn N. 2001 In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob. Agents Chemother. 45:1553-1557.[Abstract/Free Full Text]
    16. 16
  16. Livermore, D. M. 2000. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J. Antimicrob. Chemother. 46:347-350.[Free Full Text]
    17. 17
  17. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard. NCCLS publication no. M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    18. 18
  18. Nichols, R. L. 1999. Optimal treatment of complicated skin and soft tissue infections. J. Antimicrob. Chemother. 44:19-23.[Abstract/Free Full Text]
    19. 19
  19. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1994. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother. 38:2065-2072.[Abstract/Free Full Text]
    20. 20
  20. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 2003. Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials. J. Antimicrob. Chemother. 51:443-446.[Abstract/Free Full Text]
    21. 21
  21. Schmitz, F.-J., A. Fluit, S. Brisse, J. Verhoef, K. Koher, and D. Milatovic. 1999. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol. Med. Microbiol. 26:281-287.[CrossRef][Medline]
    22. 22
  22. Seltzer, E., M. B. Dorr, B. P. Goldstein, M. Perry, J. A. Dowell, T. Henkel, and the Dalbavancin Skin and Soft-Tissue Infection Study Group. 2003. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft tissue infections. Clin. Infect. Dis. 37:1298-1303.[CrossRef][Medline]
    23. 23
  23. Stevens, D. L., L. G. Smith, J. B. Bruss, M. A. McConnell-Martin, S. E. Duvall, W. M. Todd, and B. Hafkin. 2000. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44:3408-3413.[Abstract/Free Full Text]
    24. 24
  24. Streit, J. M., T. R. Fritsche, H. S. Sader, and R. N. Jones. 2004. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48:137-143.[CrossRef][Medline]
    25. 25
  25. Voss, A., D. Milatovic, C. Wallrauch-Schwarz, V. T. Rosdahl, and I. Braveny. 1994. Methicillin-resistant Staphylococcus aureus in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 13:50-55.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, February 2005, p. 770-772, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.770-772.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Marbury, T., Dowell, J. A., Seltzer, E., Buckwalter, M. (2009). Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment. J Clin Pharmacol 49: 465-476 [Abstract] [Full Text]  
  • Dowell, J. A., Goldstein, B. P., Buckwalter, M., Stogniew, M., Damle, B. (2008). Pharmacokinetic-Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic. J Clin Pharmacol 48: 1063-1068 [Abstract] [Full Text]  
  • Bailey, J., Summers, K. M. (2008). Dalbavancin: A new lipoglycopeptide antibiotic. Am J Health Syst Pharm 65: 599-610 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Rennie, R. P., Koeth, L., Jones, R. N., Fritsche, T. R., Knapp, C. C., Killian, S. B., Goldstein, B. P. (2007). Factors Influencing Broth Microdilution Antimicrobial Susceptibility Test Results for Dalbavancin, a New Glycopeptide Agent. J. Clin. Microbiol. 45: 3151-3154 [Abstract] [Full Text]  
  • Solon, E. G., Dowell, J. A., Lee, J., King, S. P., Damle, B. D. (2007). Distribution of Radioactivity in Bone and Related Structures following Administration of [14C]Dalbavancin to New Zealand White Rabbits. Antimicrob. Agents Chemother. 51: 3008-3010 [Abstract] [Full Text]  
  • Goldstein, B. P., Draghi, D. C., Sheehan, D. J., Hogan, P., Sahm, D. F. (2007). Bactericidal Activity and Resistance Development Profiling of Dalbavancin. Antimicrob. Agents Chemother. 51: 1150-1154 [Abstract] [Full Text]  
  • Bowker, K. E., Noel, A. R., MacGowan, A. P. (2006). Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother 58: 802-805 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Warren, Y. A., Tyrrell, K. L., Merriam, C. V., Fernandez, H. T. (2006). In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections.. Antimicrob. Agents Chemother. 50: 2875-2879 [Abstract] [Full Text]  
  • Fritsche, T. R., Rennie, R. P., Goldstein, B. P., Jones, R. N. (2006). Comparison of Dalbavancin MIC Values Determined by Etest (AB BIODISK) and Reference Dilution Methods Using Gram-Positive Organisms.. J. Clin. Microbiol. 44: 2988-2990 [Abstract] [Full Text]  
  • Jones, R. N., Sader, H. S., Fritsche, T. R., Hogan, P. A., Sheehan, D. J. (2006). Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.. J. Clin. Microbiol. 44: 2622-2625 [Abstract] [Full Text]  
  • Lin, S.-W., Carver, P. L, DePestel, D. D (2006). Dalbavancin: A New Option for the Treatment of Gram-Positive Infections. The Annals of Pharmacotherapy 40: 449-460 [Abstract] [Full Text]  
  • Lin, G., Smith, K., Ednie, L. M., Appelbaum, P. C. (2005). Antipneumococcal Activity of Dalbavancin Compared to Other Agents. Antimicrob. Agents Chemother. 49: 5182-5184 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, G.
Right arrow Articles by Appelbaum, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, G.
Right arrow Articles by Appelbaum, P. C.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»